Selank

The anxiolytic properties of Selank are its most thoroughly investigated feature. In studies using the elevated plus maze — a standard test for anxiety-related behavior — Selank produced calming effects comparable to diazepam, a classical benzodiazepine (5). When administered alongside diazepam under chronic stress conditions, the combination normalized anxiety markers back to pre-stress baseline, suggesting Selank may potentiate or complement benzodiazepine action through overlapping pathways (5).

Molecular work has begun to clarify how this happens. Analysis of 84 neurotransmission-related genes in the frontal cortex showed that Selank altered expression of 45 genes within an hour of administration, with changes that strongly correlated with those produced by GABA itself (7). This suggests Selank acts as an allosteric modulator of the GABAergic system — meaning it doesn't bind the receptor's main site like a benzodiazepine, but instead shifts the system's tone from a different angle. Cell-culture studies reinforced this: Selank alone produced no direct change in GABA gene expression, but when paired with GABA it nearly suppressed GABA's own gene-expression effects, consistent with a fine-tuning rather than activating role (6).

A human neuroimaging study using resting-state fMRI in 52 participants found that intranasal Selank altered functional connectivity between the right amygdala — a key anxiety hub — and regions of the right temporal cortex (2). This represents one of the first direct visualizations of Selank's acute effects on the human brain.

Beyond acute anxiety, Selank has been studied for how it helps the body weather chronic stress. In a chronic foot-shock stress paradigm, untreated subjects developed liver damage — hepatocyte degeneration, focal necrosis, and immune cell infiltration — reflecting the systemic toll of prolonged stress (3). Selank administration reduced these degenerative changes across all doses tested, with a 300 µg/kg dose producing the strongest protective effect and restoring normal cellular architecture in liver tissue (3).

The protective effect appears to extend to the immune-signaling layer of the stress response. In a social-confrontation stress model, stressed subjects showed elevated levels of inflammatory cytokines — IL-1β, IL-6, TNF-α, and TGF-β1 — molecules that drive the chronic inflammation linked to stress-related illness (8). Selank treatment reduced these inflammatory markers back toward control values while also restoring IL-4, an anti-inflammatory signal. This cytokine-balancing effect may be part of why Selank's reputation extends beyond pure anxiolysis into general stress resilience.

Selank's cognitive effects have been studied in the context of chronic alcohol exposure, a model of long-term neurological wear-and-tear. Subjects exposed to ethanol for 30 weeks developed memory and attention deficits during withdrawal, measured by performance on object recognition tasks (4). A seven-day course of Selank prevented these cognitive disturbances and also produced a measurable cognitive-stimulating effect in subjects who had not been exposed to ethanol at all.

The mechanism appears to involve BDNF — brain-derived neurotrophic factor, a key signaling protein that supports the formation and maintenance of neural connections. Chronic ethanol exposure had elevated BDNF in the hippocampus and frontal cortex in a dysregulated way, and Selank normalized these levels (4). This neurotrophin-modulating effect may explain why Selank seems to support cognition without acting as a stimulant — it appears to restore signaling balance rather than push the system harder.

One of the more striking findings in the Selank literature concerns its effect on withdrawal from opiates. In a model of naloxone-precipitated morphine withdrawal, a single injection of Selank reduced the total withdrawal syndrome index by nearly 40%, significantly attenuating convulsions, posture disturbances, and the drooping eyelid pattern characteristic of withdrawal (1). It also raised tactile sensitivity thresholds nine-fold compared to active control, suggesting it dampened the hyperalgesic state that makes withdrawal so distressing.

Selank's effects in this context were close to — though slightly less pronounced than — those of diazepam, but with an important difference: Selank itself does not appear to produce dependence in the way benzodiazepines do. This combination of withdrawal-attenuating activity without its own dependence liability is a key reason researchers have continued investigating peptide-based anxiolytics as alternatives to classical sedatives.

Reported side effects in the published research are minimal — across the laboratory studies and human investigations available, no significant adverse effects have been documented at the doses studied (2, 5). Selank does not appear to produce the sedation, cognitive dulling, or dependence patterns associated with benzodiazepines, which is one of the main reasons it has continued to attract research interest. Anecdotally, some users of intranasal preparations report mild transient effects such as a brief metallic taste or light-headedness shortly after administration, typically resolving within minutes.

The body of Selank evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far. Long-term safety in humans has not been formally characterized.